AI Has Reshaped Oncology Drug Development
Advancements in artificial intelligence are now streamlining patient-to-therapy matching and drug trials for cancer patients.
Updated on Sept. 28, 2026 in Cancer
Live Poll
Do you trust that artificial intelligence will improve the process of finding effective cancer treatments?
Artificial intelligence has become a primary driver of cancer research over the last five years. These tools are increasingly helping clinicians navigate the complex landscape of competing therapies and specialized clinical trials.
Why it matters
As the number of available treatment options grows, AI assists oncologists in managing the vast volume of data required to identify the most effective paths for individual care. This technology shift aims to simplify the increasingly granular process of disease subsetting.
Artificial intelligence has emerged as a structural shift in oncology drug development during the last 5 years. Experts note that these tools are now used to manage the complex volume of competing therapies and trials.
The players
David Spigel
As president and chief medical officer of the Sarah Cannon Research Institute, he focuses on advancing clinical cancer research and drug development programs.
Sarah Cannon Research Institute
This global research organization conducts clinical trials and evaluates emerging therapies for diverse cancer types.
The details
Artificial intelligence facilitates precision medicine by improving molecular testing, which allows providers to track treatment responses through blood-based minimal residual disease measures. These systems also assist in matching patients to appropriate clinical trials and therapies by analyzing biomarker subsets. Future methods are expected to identify patient selection factors that extend beyond traditional genetic markers.
Timeline
The Patient-Centered Oncology Care 2026 conference occurred in Nashville, Tennessee.
Artificial intelligence became a structural shift in oncology drug development during the past 5 years.
Health Landscape
The integration of AI marks a departure from traditional drug development workflows that relied solely on manual data analysis. This shift aligns with the evolving Sarah Cannon Research Institute clinical trial portfolio, which increasingly relies on high-tech biomarker analysis.
Patients may find that their oncologists are increasingly using AI-driven tools to match them with specific clinical trials based on blood-based biomarkers. It is worth discussing with your doctor how your specific biomarker profile might open new doors for personalized therapy or trial access.
The takeaway
AI is significantly narrowing the gap between rapid drug development and personalized patient care. Ask your physician if molecular testing or specialized biomarker analysis could provide more clarity on your treatment options.
Further reading
For more information on the latest research and diagnostic trends, visit the Cancer section.
Source note: This article includes information reported by Ajmc.
Live Poll
Do you trust that artificial intelligence will improve the process of finding effective cancer treatments?
